Curis receives second extension of funding from Genentech

By Angela McDaniels

Seattle, Oct. 13 - For the second time this year, Genentech has elected to extend funding to Curis, Inc. for cancer therapeutic development, Curis said.

Genentech pledged an additional $1.25 million to provide support to Curis personnel dedicated to developing Curis' Hedgehog antagonist technologies for the treatment of solid-tumor cancers.

Genentech's support was due to end in December 2005 but the extension funds the project through June 2006.

Genentech had previously funded Curis personnel and additional third-party resources managed by Curis scientists. The progress made by the two companies reduced the need for these third-party resources.

Curis established a collaboration with Genentech in June 2003 to develop a set of technologies based on inhibition of the Hedgehog signaling pathway, including small-molecule Hedgehog pathway antagonists.

Curis is a therapeutic drug development company headquartered in Cambridge, Mass. Genentech is a biotechnology company headquartered in South San Francisco.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.